Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regenerative Medicine for Joint Hypermobility and Instability
NCT07688096Phase 2Not yet recruiting
- Sponsor
- Manhattan Pain Medicine
- Start
- Jan 2027
- Primary completion
- Dec 2027
01
Overview
A Phase 2 trial of dextrose, platelet-rich plasma, doxycycline, sodium hyaluronate in joint hypermobility syndrome (HSD), joint instability, hypermobile Ehlers-Danlos syndrome (hEDS), Hypermobility Spectrum Disorder (HSD), sponsored by Manhattan Pain Medicine. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
dextroseplatelet-rich plasmadoxycyclinesodium hyaluronate
03
Conditions
joint hypermobility syndrome (HSD)joint instabilityhypermobile Ehlers-Danlos syndrome (hEDS)Hypermobility Spectrum Disorder (HSD)
Beyond the preview
Go deeper on NCT07688096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07688096.